Type-1 diabetes mellitus with insufficient serum immunoreactive insulin elevation after subcutaneous NPH-insulin injection

被引:4
|
作者
Fujimoto, S [1 ]
Matsushima, A [1 ]
Yoshitani, K [1 ]
Oya, M [1 ]
Shimono, D [1 ]
Takeda, T [1 ]
Kurose, T [1 ]
Yamada, Y [1 ]
Seino, Y [1 ]
机构
[1] Kyoto Univ, Grad Sch Med, Dept Diabet & Clin Nutr, Sakyo Ku, Kyoto 6068507, Japan
关键词
type-1 diabetes mellitus; NPH insulin; immunoreactive insulin; continuous subcutaneous insulin infusion;
D O I
10.1016/S0168-8227(02)00250-4
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We report a case of Type-1 diabetes with insufficient serum immunoreactive insulin (IRI) elevation after subcutaneous NPH-insulin injection. Favorable glycemic control was achieved by a continuous subcutaneous insulin infusion (CSII) using regular insulin. A 34-year-old woman with Type-1 diabetes (height 158 cm, weight 43.4 kg) was admitted to our hospital to improve glycemic control. On admission, her glycosylated hemoglobin (HbA(1c)) level was 10.9% and her fasting plasma glucose (FPG) level was 332 mg/dl. After admission, her insulin regimen was altered from two injections a day using premixed insulin to four injections a day using regular insulin before each meal and NPH insulin at bedtime. Although the dosage of NPH insulin at bedtime was increased to 32 U/day, there was no improvement in the FPG level. The peak IRI value after NPH insulin injection was not observed but that after the regular insulin injection was observed. Therefore, her insulin administration regimen was changed to CSII, using regular insulin alone. Her fasting plasma glucose level decreased, glycosylated hemoglobin (HbA(1c)) level improved to 7.0%, her body weight increased to 46.6 kg 4 months after starting CSII. (C) 2002 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:69 / 73
页数:5
相关论文
共 50 条
  • [1] Insulin analogues (insulin detemir and insulin aspart) in comparison with traditional human insulin (NPH-insulin and short-acting human insulin) in basal bolus therapy of type 1 diabetes mellitus
    Khermansen, K.
    Fonten, P.
    Kukolyya, K. K.
    Peterkova, V. A.
    Leyt, G.
    Gall, M.
    DIABETES MELLITUS, 2006, 9 (01): : 18 - 26
  • [2] INSULIN LOSS AT THE INJECTION SITE IN CHILDREN WITH TYPE-1 DIABETES-MELLITUS
    STEWART, NL
    DARLOW, BA
    DIABETIC MEDICINE, 1994, 11 (08) : 802 - 805
  • [3] Efficacy and safety of insulin glargine in type 1 diabetes: A 28 week randomized, NPH-insulin controlled trial.
    Ratner, RE
    Hirsch, IB
    Mecca, TE
    Wilson, CA
    DIABETOLOGIA, 1999, 42 : A234 - A234
  • [4] Pharmacokinetics and Pharmacodynamics of NPH Insulin in Type 1 Diabetes: The Importance of Appropriate Resuspension Before Subcutaneous Injection
    Lucidi, Paola
    Porcellati, Francesca
    Andreoli, Anna Marinelli
    Carriero, Ilaria
    Candeloro, Paola
    Cioli, Patrizia
    Bolli, Geremia B.
    Fanelli, Carmine G.
    DIABETES CARE, 2015, 38 (12) : 2204 - 2210
  • [5] THE INFLUENCE OF INSULIN-ANTIBODIES ON THE PHARMACOKINETICS OF NPH INSULIN IN PATIENTS WITH TYPE-1 DIABETES TREATED WITH HUMAN INSULIN
    PETERS, A
    KLOSE, O
    HEFTY, R
    KECK, F
    KERNER, W
    DIABETIC MEDICINE, 1995, 12 (10) : 925 - 931
  • [6] Switch from NPH insulin to insulin glargine, in children and adolescents with type 1 diabetes mellitus
    Spiteri, Anne
    Fuzat, Laurent
    Pradines, Sylvie
    Garnier, Philippe E.
    Papadimitriou, Dimitrios T.
    HORMONE RESEARCH, 2006, 65 : 62 - 62
  • [7] Metabolism of insulin glargine after subcutaneous injection of therapeutic dose in type 2 diabetes mellitus
    Lucidi, P.
    Porcellati, F.
    Rossetti, P.
    Candeloro, P.
    Andreoli, A. Marinelli
    Frick, A.
    Schmidt, R.
    Bolli, G. B.
    Fanelli, C. G.
    DIABETOLOGIA, 2011, 54 : S429 - S429
  • [8] Metabolism of Insulin Glargine after Subcutaneous Injection of Therapeutic Dose in Type 2 Diabetes Mellitus
    Lucidi, Paola
    Porcellati, Francesca
    Rossetti, Paolo
    Candeloro, Paola
    Andreoli, Anna Marinelli
    Frick, Annke
    Schmidt, Ronald
    Bolli, Geremia B.
    Fanelli, Carmine G.
    DIABETES, 2011, 60 : A300 - A300
  • [9] SALIVARY IMMUNOREACTIVE INSULIN IN TYPE-I DIABETIC-PATIENTS AFTER SUBCUTANEOUS INJECTION OF INSULIN
    MARCHETTI, P
    BENZI, L
    MASONI, A
    CECCHETTI, P
    GIANNARELLI, R
    DICIANNI, G
    GIOVANNITTI, MG
    CICCARONE, AM
    NAVALESI, R
    JOURNAL OF NUCLEAR MEDICINE AND ALLIED SCIENCES, 1986, 30 (04): : 185 - 189
  • [10] CONTINUOUS SUBCUTANEOUS INSULIN INFUSION THERAPY DECREASES INSULIN RESISTANCE IN TYPE-1 DIABETES
    YKIJARVINEN, H
    KOIVISTO, VA
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1984, 58 (04): : 659 - 666